Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis

Published:2015-03 Issue:2 Volume:18 Page:173-179
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Carlson Josh J.,Ogale Sarika,Dejonckheere Fred,Sullivan Sean D.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference37 articles.

1. Impact of rheumatoid arthritis on quality of life, work productivity and resource utilisation: an observational, cross-sectional study in Brazil;da Rocha Castelar Pinheiro;Clin Exp Rheumatol,2013

2. Societal cost of rheumatoid arthritis patients in the US;Birnbaum;Curr Med Res Opin,2010

3. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study;Maetzel;Ann Rheum Dis,2004

4. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

5. Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort;McWilliams;BMC Musculoskelet Disord,2013

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam;Reumatología Clínica (English Edition);2024-03

2. The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam;Reumatología Clínica;2023-10

3. Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies;Expert Review of Pharmacoeconomics & Outcomes Research;2023-08-28

4. Stairway to Heaven: Do head-to-head Trials Indicate a Need for Definite Criteria for Choosing Biologic Drugs in Rheumatoid Arthritis?;Current Rheumatology Reviews;2023-08-03

5. Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data;Modern Rheumatology;2022-04-21